SECTOR : Pharma
ENTRY DATE : 2011
EXIT DATE : 2020
BUSINESS : Venture Capital
Next generation of prophylactic vaccines against emerging diseases
Themis Bioscience GmbH develops vaccines at the pre-clinical and early clinical stages.
The Vienna-headquartered company specialises in emerging tropical diseases. The first vaccine candidates currently under development target Chikungunya and Dengue fever. Themaxyn®, the innovative platform originally developed at the Pasteur Institute in Paris and protected by a number of patents, represents the vector for all the company’s current vaccine candidates.
PRESS RELEASE(S) :
23/05/2011• Themis Bioscience completes Series A Financing round with Crédit Agricole Private Equity and Ventech
06/06/2014 • Threat of emerging virus can be stopped: Interim results of first clinical trial of Themis Bioscience’s vaccine candidate against Chikungunya fever prove successful